Trial Profile
Efficacy and safety of ozarelix acetate, a new GnRH antagonist in male patients with mild to moderate Alzheimer's Disease (Regimen: 130 mg q4w, x3).
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 21 Jun 2011
Price :
$35
*
At a glance
- Drugs Ozarelix (Primary)
- Indications Alzheimer's disease
- Focus Therapeutic Use
- 21 Jun 2011 New trial record